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Background: Approximately 15 million persons in the European Union and 10 million persons in the USA are
alcohol-dependent. The global burden of disease and injury attributable to alcohol is considerable: worldwide,
approximately one in 25 deaths in 2004 was caused by alcohol. At the same time, alcohol use disorders remain
seriously undertreated.
In this context, alternative or adjunctive therapies such as brain stimulation may play a prominent role. The early
results of studies using transcranial direct current stimulation found that stimulations delivered to the dorsolateral
prefrontal cortex result in a significant reduction of craving and an improvement of the decision-making processes
in various additive disorders. We, therefore, hypothesize that transcranial direct current stimulation can lead to a
decrease in alcohol consumption in patients suffering from alcohol use disorders.
Methods/design: We report the protocol of a randomized, double-blind, placebo-controlled, parallel-group trial, to
evaluate the efficacy of transcranial direct current stimulation on alcohol reduction in patients with an alcohol use
disorder. The study will be conducted in 14 centers in France and Monaco. Altogether, 340 subjects over 18 years
of age and diagnosed with an alcohol use disorder will be randomized to receive five consecutive twice-daily
sessions of either active or placebo transcranial direct current stimulation. One session consists in delivering a
current flow continuously (anode F4; cathode F3) twice for 13 minutes, with treatments separated by a rest interval
of 20 min. Efficacy will be evaluated using the change from baseline (alcohol consumption during the 4 weeks
before randomization) to 24 weeks in the total alcohol consumption and number of heavy drinking days. Secondary
outcome measures will include alcohol craving, clinical and biological improvements, and the effects on mood and
quality of life, as well as cognitive and safety assessments, and, for smokers, an assessment of the effects of transcranial
direct current stimulation on tobacco consumption.
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Discussion: Several studies have reported a beneficial effect of transcranial direct current stimulation on substance use
disorders by reducing craving, impulsivity, and risk-taking behavior, and suggest that transcranial direct current
stimulation may be a promising treatment in addiction. However, to date, no studies have included sufficiently
large samples and sufficient follow-up to confirm the hypothesis. Results from this large randomized controlled
trial will give a better overview of the therapeutic potential of transcranial direct current stimulation in alcohol
use disorders.
Trial registration: Clinical Trials Gov, NCT02505126 (registration date: July 15 2015).
Keywords: Addiction, Alcohol use disorder, Reduction, Transcranial direct current stimulationBackground
Alcohol use disorder (AUD) is considered a major public
health problem in Western societies [1]. Approximately
15 million persons in the European Union and 10 mil-
lion persons in the USA are alcohol-dependent. The glo-
bal burden of disease and injury attributable to alcohol
is considerable: worldwide, approximately one in 25
deaths in 2004 was caused by alcohol. In the EU in
2004, alcohol was responsible for one in seven male
deaths and one in 13 female deaths in the group aged
15–64 years [2]. As alcohol can cause more than 60 dis-
eases (cancer; vascular, endocrine, neurological diseases;
etc.), and especially many nonfatal injuries early in life,
the disability-adjusted life years (DALYs) are proportion-
ally even higher: 4.6 % of all DALYs were caused by alco-
hol (men: 7.6 %; women: 1.4 %) [3].
At the same time, AUD remain seriously undertreated.
A large treatment gap exists, given than less than 8 % of
people in Europe and less than 10.5 % of people in the
USA with a diagnosis of any alcohol disorder are actually
receiving any treatment [4–7]. One of the main reasons is
that these patients are not ready to stop drinking, and thus
are not attracted to the abstinence goals proposed by the
current psychosocial and pharmacological treatments
[8]. The availability of new treatment strategies for re-
ducing alcohol consumption would make it much eas-
ier for patients to request help to reduce their alcohol
use. Thus, new treatments supporting this strategy are
required to improve the care of patients suffering from
AUD.
In this context, alternative or adjunctive therapies such
as transcranial direct current stimulation (tDCS) and re-
petitive transcranial magnetic stimulation (rTMS), two
noninvasive brain stimulation techniques, may play a
prominent role because of their ability to modulate fo-
cally the neuronal excitability of superficial brain regions
and even deeper structures due to brain connectivity [9].
Indeed, neuroimaging studies in addictive disorders have
identified changes in prefrontal regions, in particular in
the dorsolateral prefrontal cortex (DLPFC) [10]. These
brain changes were associated with craving, manifested
by an intense desire or urge for the drug, and with animpaired inhibitory control [9, 11, 12]. Overall, the early
results of studies using rTMS and tDCS applied to the
DLPFC found a significant reduction in craving in vari-
ous addictive disorders (tobacco, alcohol, marijuana, and
methamphetamine) [12–36]. A meta-analysis of the ef-
fects of tDCS and rTMS on the DLPFC, which included
17 of these studies, provided evidence that stimulation
can decrease craving levels in various substance-related
and addictive disorders [10]. In this meta-analysis,
random-effects analysis revealed a pooled standardized
effect size (Hedge’s g) of 0.476, indicating a medium ef-
fect size, thereby favoring active stimulation over sham
stimulation in the reduction of craving. No significant
differences were found between the two brain-
stimulation techniques, even though their mechanisms
of action are somewhat different [10, 37].
Even though these results are encouraging, the large
majority of these studies were preliminary, with small
sample sizes and without follow-up of the patients. In
addition, considerable heterogeneity existed in terms of
the sample population, study design, and outcome mea-
surements. In addition, a majority of these studies fo-
cused on clinical symptoms such as craving, instead of
assessing more global and pertinent therapeutic results
such as reduced consumption or maintenance of abstin-
ence, which are the ultimate therapeutic goals for pa-
tients with substance-related and addictive disorders.
Thus, in a randomized controlled trial (RCT) involving
a large sample, we propose to evaluate, for the first time,
the clinical benefits of tDCS on the reduction of con-
sumption in patients with AUD.
Aims
The principal objective of this study is to evaluate, in
nonabstinent patients with AUD, the efficacy of 1 week
of tDCS (five consecutive twice-daily sessions) versus
placebo in reducing alcohol consumption within the
24 weeks following the treatment. The hypothesis is that
tDCS, by inducing changes in the neuronal activity of
the DLFPC to decrease the craving, can lead to a de-
crease in the consumptions of alcohol in patients suffer-
ing from AUD.
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mood, cognitive behavior, and quality of life and, in par-
ticipants who have AUD combined with tobacco use dis-
order (TUD), the effect of tDCS on tobacco craving and
consumption.Methods/design
Overview
This is a multicenter, randomized, placebo-controlled,
double-blind, parallel-group study comparing five con-
secutive two-daily sessions of active tDCS versus placebo
tDCS (Fig. 1). The study is carried out in the psychiatric
or addictology departments of 14 centers in France and
Monaco and aims to recruit 340 patients with AUD over
the course of 2 years.Fig. 1 Study flow diagramThe study protocol was approved by the independent
ethics committee (Committee for the Protection of
Persons, EST III) on 22 June 2015 under number 2015-
A00576-43 and by the French National Agency for the
Safety of Medical Products and Devices (Agence National
de Sécurité des Médicaments et des Produits de Santé).
After participants have been provided with a complete de-
scription of the study, written informed consent will be
obtained from each participant.
Inclusion criteria
Patients eligible to be enrolled in this trial according to
the following criteria will be invited to take part: (1)
male and female patients over 18 years of age, (2) who
meet the criteria for mild to severe AUD defined in the
Diagnostic and Statistical Manual of Mental Disorders-
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their alcohol consumption, and (4) have experienced at
least one prior attempt to achieve abstinence (unsuc-
cessful or relapse) or to reduce alcohol consumption.
This last criterion was included to ensure that partici-
pants had attempted the usual methods to treat AUD
before consenting to participate in a study that assesses
an experimental treatment.Exclusion criteria
Patients will be excluded if they are identified, at the in-
clusion visit, as having any of the following: (1) a breath-
alcohol concentration (BAC) > 0 milligrams per liter of
exhaled air; (2) fewer than six heavy drinking days
(HDD) in the previous 4 weeks (a day with alcohol con-
sumption ≥ 60 g for men and ≥ 40 g for women) [1]; (3)
an average alcohol consumption below the medium risk
level according to World health Organization (WHO) in
the previous 4 weeks (≤40 g/day for men; ≤ 20 g/day for
women) [38]; (4) > 3 days of abstinence prior to inclu-
sion; (5) a revised Clinical Institute Withdrawal Assess-
ment for Alcohol (CIWA) score ≥ 10 (indicating the
need for medication-supported detoxification); (6) recent
(within 1 month prior to the inclusion) treatment with
disulfiram, acamprosate, topiramate, baclofene, naltrex-
one, and nalmefene; (7) a history of pre-delirium tre-
mens and delirium tremens; (8) DSM-5 substance-use
disorder other than an alcohol or nicotine use disorder;
(9) acute psychiatric disorders that have required
hospitalization and/or immediate adjustment of psycho-
tropic medications; (10) major depression, as defined by
the Hamilton Depression rating scale (HAM-D)
greater ≥ 24 [39]; (11) recent change in psychotropic
medication (<1 month); (12) severe chronic psychiatric
disorders including schizophrenia, paranoia, or bipolar
disorder type I and II; (13) advanced liver, kidney, car-
diac, or pulmonary disease or other acute serious or un-
stable medical conditions that would compromise a
patient’s participation in the study according to the phy-
sician’s judgment; (14) contraindications to tDCS, e.g.,
metal in the head or medical devices implanted in the
brain; (15) women who are pregnant or lactating; (16)
women of childbearing potential with a positive urine β–
human chorionic gonadotrophin pregnancy test at inclu-
sion; (17) concurrent participation in another trial, em-
ployees of the investigator or trial site, or patients
protected by law; (18) persons who are not covered by
national health insurance; (19) patients, who, in the
opinion of the investigation, are not able to complete the
alcohol timeline follow-back (TLFB) and to complete
their daily alcohol consumption in a diary (derived from
the TLFB) during the 3 months of the study; and (20)
patients who refused to sign the “safety agreement”.The “safety agreement” is a paper contract that ex-
pressly notes that if a participant comes to the hospital
for a visit or a tDCS session using his/her own car and
has a BAC > 0.25 milligrams per liter of exhaled air
(which prohibits a person from driving a car in France),
he/she will agree to give his/her car keys to the medical
staff and authorize the staff to call a member of his/her
family or a friend to take the patient home if the patient
is unable to use public transport.
Study process
The study will have three phases (Fig. 1):
1) During the first phase, subjects will be screened
using the inclusion and exclusion criteria.
Information on the implementation of the study and
the objectives of the research will be given to each
subject. Inclusion and tDCS treatment will be
scheduled in the following weeks for eligible
participants.
2) The second phase will correspond to both the
inclusion of participants and the period of the tDCS
sessions. This phase will always begin on Monday with
five steps: (1) participants will be evaluated for study
eligibility based on the inclusion and exclusion criteria;
(2) they will have to sign the informed consent and the
“safety agreement” after it has been ascertained that the
participant has a zero alcohol-blood level using breath
alcohol concentration; (3) a clinical (including alcohol
TLFB) and biological baseline
assessment will be performed (visit 1); (4), included
participants will be randomized to active or placebo
tDCS; and (5), the first tDCS will be delivered.
3) Then, daily sessions will be performed during the
following days up to Friday. The second phase will
end by a clinical assessment (visit 2) once the last
tDCS session has been delivered.
4) The third phase will be a 6-month follow-up phase
without treatment. A clinical assessment will be
performed every 4 weeks (visits 3 to 8), and the
biochemical markers of alcohol consumption will be
measured at 1, 3, and 6 months after the end of the
stimulation (visits 3, 5, and 8).
Interventions
For tDCS, a StarStim wireless tDCS neurostimulator
(Neuroelectrics, Barcelona, Spain) will be used. It can
deliver a maximum current of plus/minus 2 mA per
electrode. Direct currents will be applied via a pair of
0.9 % NaCl-soaked surface sponge electrodes (25 cm2).
According to the 10–20 international system, the anode
will be placed over F4 (right DLPFC), and the cathode,
over F3 (left DLPFC). Patients will receive two consecu-
tive 13-min anodal tDCS sessions (2 mA) per day on 5
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separated by an interval of 20 min. Each of the two ses-
sions will have a ramp-in and ramp-out of 15 s each.
This pattern of stimulation (anode F4; 13:20:13 min) is
in accordance with the study of Klauss, who found that
these stimulation parameters for tDCS had a long-
lasting, beneficial, modulatory effect on alcohol-use re-
lapse at 6 months [12].
The StarStim wireless tDCS neurostimulator includes
a study mode for double-blind studies. The study mode
encodes sham and active stimulation. Numerous sham
and active stimulation protocols will be created and
numbered without providing information related to the
set-up. At the inclusion of a patient, the administrator
will assign the subject to one of the protocols previously
recorded in StarStim. During the stimulation, the oper-
ator will not have access to protocol data to preserve
double-blinding. Sham stimulation will be given using a
similar pattern of stimulation to that in the active group.
With sham stimulation, the initial ramp-up phase of
15 s (also up to 2 mA) will be immediately followed by a
ramp down phase of 30 seconds. A second ramp-up
(30 s) and down (15 s) phase will be delivered 13 min
later in order to envelop the beginning and the end of a
session’s stimulation. Using this pattern of sham stimula-
tion, we hope to improve sham conditions both for par-
ticipants and assessor blinding by inducing skin
sensation and skin redness in the immediate poststimu-
lation period, even though no 13-minute stimulation
period occurred.
Randomization
Randomization will be performed directly though the se-
cure CleanWebTM internet-based software after identifi-
cation of the investigator by a personal password (website
https://chu-dijon.tentelemed.com). The inclusion criteria
and the absence of exclusion criteria will be validated be-
fore the randomization can be done. Investigators and pa-
tients will be blinded to the treatment assignment. The
treatment algorithms will be determined by the study stat-
istician. This allocation will be based on a minimization
technique taking into account the center. Patients will be
randomly assigned to one of the two groups in a 1:1 ratio.
A comprehensive document describing the randomization
procedure will be kept in a confidential manner at the
Unité de Soutien Méthodologique, Direction of Clinical
Research, University Hospital of Dijon, Francel.
Outcomes
In the “Guideline on the development of medicinal products
for the treatment of alcohol dependence,” for an alcohol re-
duction strategy, the European Medicines Agency (EMA)
recommend using a co-primary efficacy outcome, the
change from baseline in total alcohol consumption(TAC) per month and a reduction in the number of
heavy drinking days (HDD) [1]. Thus, our principal ef-
fective criteria on alcohol reduction will be both the
change in TAC from baseline to week 24, defined as
mean daily alcohol consumption over 28 days (in g/
day), and the number of HDD, defined as more than
60 grams of pure alcohol in men and 40 grams in
women consumed in one day. Baseline will be defined
as alcohol consumption during the 28 days before
randomization using the alcohol TLFB method, a vali-
dated method that retrospectively obtains estimates of
daily drinking using a calendar [40, 41].
The secondary evaluation criteria will be the change
from baseline to the end of the tDCS cessions and, then,
for each 4-week period after the treatment up to week
24 in the following parameters:
– TAC (g/day) and number of HDD
– Proportion of subjects with a significant categorical
shift in World Health Organization (WHO) risk
levels of drinking: low risk (H ≤ 40 g/d; F ≤ 20 g/d),
medium risk (H ≤ 60 g/d; F ≤ 40 g/d), high risk (H ≤
100 g/d; F ≤ 60 g/d, and very high risk (H > 100 g/d;
F > 60 g/d) [38]
– Proportion of subjects with a 50 %, 70 %, and 90 %
reduction in alcohol consumption, as well as, the
proportion of patients who potentially achieve
abstinence
– Level of alcohol dependence severity (alcohol
dependence scale)
– Craving/urge to drink assessment (visual analog
scale, obsessive compulsive drinking scale)
– Clinical global impression—severity and
improvement
– Scores for depression scales (Hamilton depression
rating scale—17 items)
– Quality of life (short form health survey—12 items)
Other secondary evaluation criteria will include the
change from baseline at week 4, week 12, and week 24
after the treatment, in the following:
– Biochemical alcohol consumption markers (gamma
glutamyl transferase, mean corpuscular volume,
aspartate aminotransferase, alanine aminotransferase,
and carbohydrate deficient transferrin)
– Cognitive assessment (Montreal cognitive
assessment)
– Number of cigarettes smoked/day and craving for
tobacco (visual analog scale, tobacco-craving
questionnaire) for smokers.
The number of patients with adverse events will be de-
termined at the time of each visit.
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As the primary efficacy outcome, the EMA recommends
using both TAC and the number of HDD [1]. Besides, any
reduction in total alcohol consumption of at least 10 g/
day for patients with alcohol use disorders will reduce the
annual and lifetime risk of alcohol-related death [3].
In this context, a sample size calculation based on an
expected difference between the treatment groups of
10 g/day in total alcohol consumption, with a standard
deviation for the TAC of 30 g/day and with an autocor-
relation of 0.7 between observations in the same subject,
indicates that 274 patients would be required.
By considering a significance level of 1.25 % (co-pri-
mary outcome), a power of 80 %, and with the hypoth-
esis of a premature drop-out or a noninitiation of the
treatment (acute repeated alcoholism) for 20 % of the
patients, 340 patients (170 per group) should be in-
cluded to meet the objectives of the study.
Statistical analysis
All randomized patients will be used for the efficacy ana-
lyses. The baseline and demographic characteristics of the
two groups (active tDCS vs placebo tDCS) will be recorded.
Qualitative variables will be described in terms of numbers
and percentages, and quantitative variables, in terms of
means and standard deviations or medians and interquar-
tile intervals. The co-primary outcome of change in TAC
from baseline and reduction in the number of HDD at
6 months after treatment and its association with tDCS will
be analyzed under the intention-to-treat principle using
mixed model repeated measures (eight times).
The comparability of the two groups at baseline will
be evaluated using the chi square test or Fisher’s test for
qualitative variables, and Student’s T test or the Mann
Whitney test for continuous variables. Then, a mixed
model repeated measures will be conducted to estimate
the effect of treatment on the TAC first, and HDD sec-
ond. Observed cases will be considered random effects,
and the site, sex, time, and treatment as the fixed effects.
We will use multiple imputation techniques to compen-
sate for any potential bias introduced by missing end-
point data [42].
For the primary outcome, per-protocol analysis will also
be conducted among the participants who have completed
baseline and endpoint assessments. The secondary out-
come measurements will be analyzed with similar models
to those used for the co-primary, continuous variables,
and logistic regression, for dichotomized outcomes.
All tests will be one-sided. The primary results will be ex-
amined at a significance level of 0.0125 (co-primary out-
come). For secondary outcomes, the threshold for
significance will be fixed at 0.025. All analyses will be per-
formed using SAS version 9.3 (SAS Institute, Inc, Cary,
NC, USA) by the team of statisticians of the Unité deSoutien Méthodologique, Direction of Clinical Research,
University Hospital of Dijon, France.Discussion
In recent years, tDCS has proved to be a promising tool in
the treatment of various neurologic and psychiatric disor-
ders [43]. More recently, some studies have shown that
tDCS targeting the DLPFC may to be of interest to treat pa-
tients with substance-related and addictive disorders by act-
ing on craving reduction and other mechanisms, such as
the improvement in cognitive dysfunctions that underlie
addictive disorders [12, 30–34, 36, 44]. Among these stud-
ies, only three have been performed for patients treated for
AUD, and these used an abstinence-based strategy. They
found interesting results in terms of craving reduction,
modulation of the decision-making processes, improve-
ments in the quality of life, and reduction of alcohol relapse
for one of them [12, 33, 34]. However, none considered
studying tDCS in a strategy based on reducing alcohol con-
sumption, even though a number of benefits can be ex-
pected, such as a reduction in alcohol-related damage and
better acceptability of the therapeutic goal [8]. This strategy
could be even more attractive, given the short-term treat-
ment (i.e., a few days of brain stimulation) and the fact that
tDCS is known to be safe [45, 46]. In addition, tDCS de-
vices are easy to use, portable, and could be used in primary
care and even at home [47].
Although some research has indicated that tDCS may be
effective in AUD and other substance-use disorders, these
conclusions are preliminary, mainly because these studies
are limited by small sample sizes. Thus, we aim to conduct
an RCT with a large sample size to investigate whether or
not a tDCS treatment strategy has the potential to become
a promising treatment in AUD, in particular by determin-
ing whether tDCS has long-lasting effects in patients with
AUD. Indeed, Klauss et al. found a lower rate of relapse at
6 months in patients with AUD treated with tDCS, but
their study included only 33 participants, and the follow-up
was based on information gathered by self-reports or re-
ports of family members through visits and by telephone
calls [12]. We hope that our study will remedy these short-
comings and provide a high level of evidence of the short
and long-term efficacy of modulating DLPFC excitability
via tDCS to treat AUD. This trial, which is one of the lar-
gest RCTs to assess the efficacy of tDCS in substance-
related and addictive disorders, may also shed light on
whether noninvasive brain stimulation techniques are of
interest in the comprehensive treatment of addiction.Trial status
Enrolment for this study began on 16 November 2015.
At the time of submission, we had enrolled two
participants.
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